Timothy J. Wilt, MD, MPH

home / authors / timothy-j-wilt-md-mph

Articles

PSA Testing in Prostate Cancer: Early Treatment vs Observation

H. Ballentine Carter, MD;Timothy J. Wilt, MD, MPH

March 21st 2014

In this interview we discuss the role of early treatment, active surveillance, and watchful waiting in patients with PSA-detected early-stage prostate cancer.

The Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Timothy J. Wilt, MD, MPH;Michael K. Brawer, MD;Timothy J. Wilt, MD, MPH;Michael K. Brawer, MD;Jamie Barnhill, PhD;Michael J. Barry, MD;Brent Blumenstein, PhD;Joseph Collins, ScD;Arthur Crowley, MD;Daniel J. Culkin, MD, FACS, MBA;Charles Johnson, MD;Richard Kaplan, MD;Timothy Moon, MD;Ian Thompson, MD;David Weiss, PhD;Thomas Wheeler, MD

August 1st 1997

The Prostate Cancer Intervention Versus Observation Trial (PIVOT) is a randomized trial designed to determine whether radical prostatectomy or expectant management provides superior length and quality of life for men with clinically localized prostate cancer. Conducted at Department of Veterans Affairs and National Cancer Institute medical centers, PIVOT will enroll over 1,000 individuals less than 75 years of age. The primary study end point is all-cause mortality. Secondary outcomes include prostate cancer- and treatment-specific morbidity and mortality, health status, predictors of disease-specific outcomes, and cost-effectiveness. Within the first 3 years of enrollment, over 400 men have been randomized. Early analysis of participants' baseline characteristics indicate that enrollees are representative of men diagnosed with clinically localized prostate cancer throughout the United States. Therefore, results of PIVOT will be generalizable. These results are necessary in order to determine the preferred therapy for clinically localized prostate cancer. [ONCOLOGY 11(8):1133-1143, 1997]